Clinical Trial Update: Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea [Phase 1]

View source ↗

Summary

Phase 1 trial update describing safety and tolerability of AZD1656 in type 2 diabetes mellitus patients treated with metformin and sulfonylurea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656

Snippet

Sponsor: AstraZeneca | Conditions: Type II Diabetes Mellitus | Phase 1 | Status: COMPLETED